DRUG SURVIVAL ON FIRST TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: COMPARISON ACROSS ETANERCEPT, ADALIMUMAB, GOLIMUMAB AND INFLIXIMAB

被引：0
|
作者：
Garcia-Porrua, C. [1 ]
Maceiras-Pan, F. [2 ]
Fernandez-Dominguez, L. [3 ]
Mosquera-Martinez, J. A. [4 ]
Correa-Rey, B. [5 ]
Pombo-Suarez, M. [6 ]
Pinto-Tasende, J. [7 ]
机构：
[1] HU Locus Augusti, Rheumatol, Lugo, Spain
[2] CHU Vigo, Rheumatol, Vigo, Spain
[3] CHU Ourense, Rheumatol, Ourernse, Spain
[4] CHU Pontevedra, Rheumatol, Pontevedra, Spain
[5] CHU Arquitecto Marcide Naval, Rheumatol, Ferrol, Spain
[6] CHU Santiago, Rheumatol, Santiago De Compostela, Spain
[7] INIBIC XXI A Coruna, Rheumatol, La Coruna, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.4951
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0333
引用
收藏
页码：1031 / 1031
页数：1
相关论文
共 50 条
  • [1] Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
    Neovius, M.
    Arkema, E. V.
    Olsson, H.
    Eriksson, J. K.
    Kristensen, L. E.
    Simard, J. F.
    Askling, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 354 - 360
  • [2] Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
    Hebeisen, Monika
    Scherer, Almut
    Micheroli, Raphael
    Nissen, Michael J.
    Tamborrini, Giorgio
    Moller, Burkhard
    Zufferey, Pascal
    Exer, Pascale
    Ciurea, Adrian
    PLOS ONE, 2019, 14 (05):
  • [3] Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis
    Fenix-Caballero, S.
    Alegre-del Rey, E. J.
    Castano-Lara, R.
    Puigventos-Latorre, F.
    Borrero-Rubio, J. M.
    Lopez-Vallejo, J. F.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (04) : 286 - 293
  • [4] A COMPARISON OF DRUG SURVIVAL TIMES FOR INFLIXIMAB, ADALIMUMAB AND ETANERCEPT
    Pocock, Joanna M.
    Albreshni, Samir
    Slack, Ruth
    Polydoropoulou, Varvara
    O'Reilly, David
    Oestoer, Andrew J.
    RHEUMATOLOGY, 2009, 48 : I69 - I69
  • [5] Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis
    Dafna D Gladman
    Nature Clinical Practice Rheumatology, 2008, 4 : 510 - 511
  • [6] Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis
    Gladman, Dafna D.
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (10): : 510 - 511
  • [7] Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
    Skov, Lone
    Kragballe, Knud
    Dam, Tomas
    Poulsen, Johan Holk
    Obitz, Erik
    Gniadecki, Robert
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S61 - S61
  • [8] Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
    Gniadecki, R.
    Kragballe, K.
    Dam, T. N.
    Skov, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (05) : 1091 - 1096
  • [9] Drug-survival, effectiveness and safety of infliximab, adalimumab and etanercept in rheumatoid arthritis patients
    Flendrie, M.
    Creemers, M. C. W.
    Welsing, P. M. J.
    Van den Hoogen, F. H. J.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 191 - 191
  • [10] DRUG DISCONTINUATION IN 6,657 PATIENTS WITH RA STARTING THEIR FIRST TNF INHIBITOR: COMPARISON OF ADALIMUMAB, ETANERCEPT & INFLIXIMAB
    Neovius, M.
    Arkema, E.
    Olsson, H.
    Eriksson, J.
    Simard, J.
    Askling, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 368 - 368
12345